FAQ: NanoViricides' NV-387 Dual-Track Clinical Strategy and Broad-Spectrum Antiviral Platform
Summary
NanoViricides is advancing NV-387, a broad-spectrum antiviral drug candidate using nano-polymer micelle technology that targets MPox and respiratory viruses including influenza, coronaviruses, and RSV. The company plans Phase 2 trials for MPox in Congo by late 2025/early 2026 and highlights potential U.S. biodefense funding opportunities through BARDA.
What is NanoViricides’ NV-387 and what viruses does it target?
NV-387 is NanoViricides’ broad-spectrum antiviral drug candidate that targets both MPox and respiratory viral infections including influenza, coronaviruses, and RSV. The company also plans to develop it as a treatment for COVID, long COVID, and other respiratory viral infections.
How does NV-387’s technology work to combat viruses?
NV-387 uses nano-polymer micelle technology that binds and neutralizes virus particles before they can infect cells. This mechanism prevents viral entry into host cells, potentially stopping infection at the earliest stage.
What is the current clinical development status and timeline for NV-387?
Following completion of a Phase 1 safety and tolerability study in 2023, NanoViricides plans to initiate a Phase 2 trial for MPox in Congo by late 2025 or early 2026. The company has already secured ethics approval for this trial.
What are the potential funding opportunities mentioned for NV-387?
The report highlights potential U.S. biodefense funding opportunities through BARDA (Biomedical Advanced Research and Development Authority) based on successful trial outcomes. This could provide significant financial support for further development.
What other drug candidates is NanoViricides developing besides NV-387?
NanoViricides is also developing NV-HHV-1 for shingles treatment, NV-CoV-2 and NV-CoV-2-R for COVID-19, and drugs against oral/genital herpes, viral eye diseases, various influenza strains, HIV, hepatitis C, rabies, dengue fever, and Ebola virus.
How does NanoViricides’ business model and technology licensing work?
NanoViricides licenses technology from TheraCour Pharma Inc. for specific antiviral applications, holding broad, exclusive, sub-licensable field licenses. The company has a Memorandum of Understanding with TheraCour for developing drugs based on these technologies for all antiviral infections.
What is the difference between NV-CoV-2 and NV-CoV-2-R?
NV-CoV-2 is NanoViricides’ drug candidate for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R contains NV-387 with remdesivir encapsulated within its polymeric micelles. The company believes the remdesivir-containing version may be more readily approvable since remdesivir is already FDA-approved.
Where can I find more information about this announcement?
To view the full press release, visit https://ibn.fm/ib5Cg. More information about NanoViricides is available at their investor brand network page.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 254045